Page last updated: 2024-09-05

sorafenib and vidarabine

sorafenib has been researched along with vidarabine in 2 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(vidarabine)
Trials
(vidarabine)
Recent Studies (post-2010) (vidarabine)
6,5207305,2514,9769741,525

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)vidarabine (IC50)
Dipeptidyl peptidase 4Homo sapiens (human)0.062

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andersson, BS; Champlin, RE; Li, Y; Liu, Y; Song, G; Valdez, BC1
Aymerich, M; Bataller, A; Camós, M; Colomer, D; Díaz-Beyá, M; Esteve, J; Garrote, M; López-Guerra, M; Oliver-Caldés, A; Vega-García, N1

Other Studies

2 other study(ies) available for sorafenib and vidarabine

ArticleYear
Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:11

    Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinonucleosides; Busulfan; Clofarabine; DNA Damage; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Phosphorylation; Sorafenib; Tandem Repeat Sequences; Vidarabine

2014
Early T-cell precursor lymphoblastic leukaemia: response to FLAG-IDA and high-dose cytarabine with sorafenib after initial refractoriness.
    British journal of haematology, 2019, Volume: 185, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sorafenib; Treatment Outcome; Vidarabine

2019